StockData
Connect Biopharma Holdings Ltd logo

Connect Biopharma Holdings Ltd (CNTB) stock

CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.67+0.09 (+14.93%)

Close on Nov 18, 2026Market cap $41.89MP/E –Yield –

Connect Biopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Connect Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$70.41M. For fiscal 2025 it was -$58.07M. The highest annual figure on record is -$22.45M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$58.07M–
FY2024Dec 31, 2024-$22.45M–
FY2023Dec 31, 2023-$69.06M–
FY2022Dec 31, 2022-$119.32M–
FY2021Dec 31, 2021-$98.11M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.60M–
Q1 FY2026Mar 31, 2026-$19.61M–
Q4 FY2025Dec 31, 2025-$15.53M–
Q3 FY2025Sep 30, 2025-$17.68M–
Q2 FY2025Jun 30, 2025-$13.42M-198.4%
Q1 FY2025Mar 31, 2025-$11.45M–
Q4 FY2024Dec 31, 2024-$9.62M–
Q3 FY2024Sep 30, 2024-$13.85M–
Q2 FY2024Jun 30, 2024$13.65M–
Q1 FY2024Mar 31, 2024-$12.63M–

More Connect Biopharma figures

See a number that looks wrong?